Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover Baxter's acquisition of Apatech, the growth in biomarker-based tests in oncology, the CREST trial's positive results for carotid stenting, and new directions from FDA on how to plan pre-approval trials for novel cardiovascular combination products.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

U.S., Japan Regulators Begin Collaborative Review Pilot With Femoral Stents

FDA and Japanese regulators recently began to work together to review two devices - one U.S.-manufactured, one Japanese-made - that are part of a new pilot program intended to model how products can achieve faster market entry in both countries

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel